Age/years, median (range)
|
63 (22–88)
|
68 (33–83)
|
0.138
|
52 (25–72)
|
50 (18–69)
|
0.450
|
Age group/no. (%), years
| | |
0.652
| | |
0.793
|
< 60
|
16 (35.6)
|
13 (28.9)
| |
27 (75.0)
|
25 (69.4)
| |
≥ 60
|
29 (64.4)
|
32 (71.1)
| |
9 (25.0)
|
11 (30.6)
| |
Gender/no. (%)
| | |
0.289
| | |
1.000
|
Male
|
28 (62.2)
|
22 (48.9)
| |
21 (58.3)
|
20 (55.6)
| |
Female
|
17 (37.8)
|
23 (51.1)
| |
15 (41.7)
|
16 (44.4)
| |
WBC/× 109/L, median (range)
|
15.2 (0.7–298.4)
|
16.9 (1.0–297.4)
|
0.589
|
30.3 (1.5–98.8)
|
28.3 (0.6–223.8)
|
0.978
|
BM blast/ %, median (range)
|
67 (30–98)
|
75 (37–99)
|
0.050
|
68 (30–97)
|
76 (35–100)
|
0.131
|
PB blast/%, median (range)
|
18 (0–71)
|
53 (0–98)
|
0.002
|
41 (0–85)
|
53 (0–96)
|
0.116
|
FAB subtypes/no. (%)
|
M0
|
0 (0.0)
|
8 (17.8)
|
0.006
|
3 (8.3)
|
6 (16.7)
|
0.478
|
M1
|
7 (15.6)
|
13 (28.9)
|
0.201
|
8 (22.2)
|
15 (41.7)
|
0.129
|
M2
|
13 (28.9)
|
8 (17.8)
|
0.231
|
13 (36.1)
|
6 (16.7)
|
0.107
|
M4
|
14 (31.1)
|
10 (22.2)
|
0.340
|
8 (22.2)
|
6 (16.7)
|
0.767
|
M5
|
9 (20)
|
4 (8.9)
|
0.230
|
3 (8.3)
|
1 (2.8)
|
0.614
|
M6
|
0 (0.0)
|
1 (2.2)
|
1.000
|
1 (2.8)
|
0 (0.0)
|
1.000
|
M7
|
1 (2.2)
|
1 (2.2)
|
1.000
|
0 (0.0)
|
1 (2.8)
|
1.000
|
Others
|
1 (2.2)
|
0 (0.0)
|
1.000
|
0 (0.0)
|
1 (2.8)
|
1.000
|
Karyotype/no. (%)
|
Normal
|
21 (46.7)
|
23 (51.1)
|
0.833
|
17 (47.2)
|
17 (47.2)
|
1.000
|
Complex
|
5 (11.1)
|
7 (15.6)
|
0.758
|
5 (13.9)
|
7 (19.4)
|
0.753
|
MLL rearranged
|
2 (4.4)
|
1 (2.2)
|
1.000
|
2 (5.6)
|
1 (2.8)
|
1.000
|
CBFβ-MYH11
|
7 (15.6)
|
0 (0.0)
|
0.012
|
5 (13.9)
|
0 (0.0)
|
0.054
|
BCR-ABL1
|
1 (2.2)
|
0 (0.0)
|
1.000
|
1 (2.8)
|
1 (2.8)
|
1.000
|
RUNX1-RUNX1T
|
5 (11.1)
|
1 (2.2)
|
0.203
|
0 (0.0)
|
1 (2.8)
|
1.000
|
Others
|
4 (8.9)
|
13 (28.9)
|
0.029
|
6 (16.7)
|
9 (25)
|
0.563
|
Risk (cyto)/no. (%)
|
Good
|
12 (26.7)
|
1 (2.2)
|
0.002
|
5 (13.9)
|
1 (2.8)
|
0.199
|
Intermediate
|
20 (44.4)
|
30 (66.7)
|
0.056
|
17 (47.2)
|
24 (66.7)
|
0.153
|
Poor
|
13 (28.9)
|
12 (26.7)
|
1.000
|
13 (36.1)
|
11 (30.6)
|
0.803
|
Others
|
0 (0.0)
|
2 (4.4)
|
0.494
|
1 (2.8)
|
0 (0.0)
|
1.000
|
FLT3-ITD/no. (%)
| | |
1.000
| | |
0.396
|
Presence
|
8 (17.8)
|
8 (17.8)
| |
6 (16.7)
|
10 (27.8)
| |
Absence
|
37 (82.2)
|
37 (82.2)
| |
30 (83.3)
|
26 (72.2)
| |
NPM1/no. (%)
| | |
0.367
| | |
0.430
|
Presence
|
12 (26.7)
|
17 (37.8)
| |
8 (22.2)
|
12 (33.3)
| |
Absence
|
33 (73.3)
|
28 (62.2)
| |
28 (77.8)
|
24 (66.7)
| |
DNMT3A/no. (%)
| | |
0.059
| | |
0.415
|
Presence
|
8 (17.8)
|
17 (37.8)
| |
7 (19.4)
|
11 (30.6)
| |
Absence
|
37 (82.2)
|
28 (62.2)
| |
29 (80.6)
|
25 (69.4)
| |
RUNX1/no. (%)
| | |
0.058
| | |
1.000
|
Presence
|
1 (2.2)
|
7 (15.6)
| |
4 (11.1)
|
4 (11.1)
| |
Absence
|
44 (97.8)
|
38 (84.4)
| |
32 (88.9)
|
32 (88.9)
| |
MLL-PTD/no. (%)
| | |
1.000
| | |
0.115
|
Presence
|
2 (4.4)
|
3 (6.7)
| |
4 (11.1)
|
0 (0.0)
| |
Absence
|
43 (95.6)
|
42 (93.3)
| |
32 (88.9)
|
36 (100.0)
| |
TP53/no. (%)
| | |
1.000
| | |
1.000
|
Mutation
|
5 (11.1)
|
5 (11.1)
| |
2 (5.6)
|
2 (5.6)
| |
Wild type
|
40 (88.9)
|
40 (88.9)
| |
34 (94.4)
|
34 (94.4)
| |
CEBPA/no. (%)
| | |
1.000
| | |
1.000
|
Mutation
|
2 (4.4)
|
1 (2.2)
| |
4 (11.1)
|
4 (11.1)
| |
Wild type
|
43 (95.6)
|
44 (97.8)
| |
32 (89.9)
|
32 (88.9)
| |
IDH1/no. (%)
| | |
0.012012
| | |
0.514
|
Mutation
|
0 (0.0)
|
7 (15.6)
| |
4 (11.1)
|
7 (19.4)
| |
Wild type
|
45 (100.0)
|
38 (84.4)
| |
32 (88.9)
|
29 (80.6)
| |
IDH2/no. (%)
| | |
1.000
| | |
0.710
|
Mutation
|
4 (8.9)
|
5 (11.1)
| |
3 (8.3)
|
5 (13.9)
| |
Wild type
|
41 (91.1)
|
40 (88.9)
| |
33 (91.7)
|
31 (86.1)
| |